Clinical Trials
249 trialsNCT05773326 2026-05-14
Superselective Intra-arterial Cerebral Infusion of Temsirolimus in HGG
St. Joseph's Hospital and Medical Center, Phoenix
Phase EARLY_PHASE1 Terminated
NCT03382977 2026-05-08
Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects
VBI Vaccines Inc.
Phase 1/2 Terminated
NCT05557292 2026-05-06
RMC-5552 Monotherapy in Adult Subjects With Recurrent Glioblastoma
University of California, San Francisco
Phase 1 Terminated
NCT05091866 2026-05-05
Natural Progesterone for the Treatment of Recurrent Glioblastoma
Emory University
Phase EARLY_PHASE1 Terminated
NCT05934630 2026-04-23
Testing Cerebrospinal Fluid for Cell-free Tumor DNA in Children, Adolescents, and Young Adults With Brain Tumors
Pediatric Brain Tumor Consortium
Terminated
NCT05275478 2026-04-15
Safety and Tolerability of TNG908 in Patients With MTAP-deleted Solid Tumors
Tango Therapeutics, Inc.
Phase 1/2 Terminated
NCT01507506 2026-04-14
SPECTRO GLIO
Institut Claudius Regaud
Phase 3 Terminated
NCT01743950 2026-03-25
A Phase II Study of Pulse Reduced Dose Rate Radiation Therapy With Bevacizumab
University of Wisconsin, Madison
Phase 2 Terminated
NCT05753007 2026-03-16
A Clinical Trial of a Hemp-Derived, High Cannabidiol Product for Anxiety in Glioblastoma Patients
Mclean Hospital
Phase 2 Terminated
NCT01068782 2026-02-25
Multiple Doses and Regimens of Cabozantinib in Subjects With Grade IV Astrocytic Tumors in First or Second Relapse
Exelixis
Phase 2 Terminated
NCT02942264 2026-02-23
Zotiraciclib (TG02) Plus Dose-Dense or Metronomic Temozolomide Followed by Randomized Phase II Trial of Zotiraciclib (TG02) Plus Temozolomide Versus Temozolomide Alone in Adults With Recurrent Anaplastic Astrocytoma and Glioblastoma
National Institutes of Health Clinical Center (CC)
Phase 1/2 Terminated
NCT04825275 2026-01-23
Neuro-pharmacological Properties of Repurposed Posaconazole in Glioblastoma: A Phase 0 Clinical Trial
Milton S. Hershey Medical Center
Phase EARLY_PHASE1 Terminated
NCT04869449 2026-01-07
Neuro-pharmacological Properties of Repurposed Ketoconazole in Glioblastomas
Milton S. Hershey Medical Center
Phase EARLY_PHASE1 Terminated
NCT05267106 2025-12-30
FIGHT-209
Incyte Corporation
Phase 2 Terminated
NCT05977322 2025-12-24
A Phase I Study of [177Lu]Lu-FF58 in Patients With Advanced Solid Tumors.
Novartis
Phase 1 Terminated
NCT06359379 2025-12-18
Ropidoxuridine as a Radiosensitizer in Newly Diagnosed IDH-Wildtype Glioblastoma With Unmethylated MGMT Promoter
Shuttle Pharmaceuticals, Inc.
Phase 2 Terminated
NCT03107780 2025-11-13
Testing the Ability of AMG 232 (KRT 232) to Get Into the Tumor in Patients With Brain Cancer
National Cancer Institute (NCI)
Phase 1 Terminated
NCT04209790 2025-11-10
NeoGlio
Geisinger Clinic
Phase 2 Terminated
NCT04424966 2025-10-24
Infigratinib in Recurrent High-Grade Glioma Patients
St. Joseph's Hospital and Medical Center, Phoenix
Phase EARLY_PHASE1 Terminated
NCT02711137 2025-10-21
Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies
Incyte Corporation
Phase 1/2 Terminated
NCT03868943 2025-10-21
JAZZ
Wake Forest University Health Sciences
Phase 2 Terminated
NCT04982926 2025-10-14
A Study of TAS2940 in Participants With Locally Advanced or Metastatic Solid Tumor Cancer
Taiho Oncology, Inc.
Phase 1 Terminated
NCT04712721 2025-10-10
Study of [68Ga]-FF58 in Patients With Selected Solid Tumors Expected to Overexpress αvβ3 and αvβ5 Integrins.
Novartis
Phase EARLY_PHASE1 Terminated
NCT01849952 2025-09-15
Evaluating the Expression Levels of MicroRNA-10b in Patients With Gliomas
Dartmouth-Hitchcock Medical Center
Terminated
NCT03347617 2025-09-09
Ferumoxytol MRI in Assessing Response to Pembrolizumab in Patients With Glioblastoma
OHSU Knight Cancer Institute
Phase 2 Terminated
NCT03149575 2025-09-04
STAR-3
Kintara Therapeutics, Inc.
Phase 3 Terminated
NCT04074785 2025-08-17
SCCC-06319
University of Texas Southwestern Medical Center
Phase EARLY_PHASE1 Terminated
NCT03330197 2025-08-12
A Study of Ad-RTS-hIL-12 + Veledimex in Pediatric Subjects With Brain Tumors Including DIPG
Alaunos Therapeutics
Phase 1/2 Terminated
NCT03018288 2025-08-08
Radiation Therapy Plus Temozolomide and Pembrolizumab With and Without HSPPC-96 in Newly Diagnosed Glioblastoma (GBM)
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT04963413 2025-08-06
RENEW: Feasibility of CMV RNA-Pulsed Dendritic Cells Vaccines for the Treatment of Newly Diagnosed Glioblastoma Patients.
University of Florida
Phase 1 Terminated
NCT06038760 2025-07-30
PEAR-GLIO
Ourotech, Inc.
Terminated
NCT05563272 2025-07-10
STARBURST
Telix Pharmaceuticals (Innovations) Pty Limited
Phase 2 Terminated
NCT03287063 2025-07-01
Study Using Genomic, Histologic and Radiomic Analysis to Evaluate Regional Tumor Heterogeneity in Patients Undergoing Surgery for Newly Diagnosed Glioblastoma
University of Michigan Rogel Cancer Center
Terminated
NCT04406272 2025-06-10
VB-111 in Surgically Accessible Recurrent/Progressive GBM
Dana-Farber Cancer Institute
Phase 2 Terminated
NCT05297864 2025-05-23
OU-SCC-PI-4G
University of Oklahoma
Phase 2 Terminated
NCT01430351 2025-05-07
Temozolomide, Memantine Hydrochloride, Mefloquine, and Metformin Hydrochloride in Treating Patients With Glioblastoma Multiforme After Radiation Therapy
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT05388435 2025-05-04
Safety, Tolerability, PK/PD & Preliminary Efficacy of SKL27969 in Advanced Solid Tumors Patients
SK Life Science, Inc.
Phase 1/2 Terminated
NCT04006119 2025-04-18
Study of Ad-RTS-hIL-12 + Veledimex in Combination With Cemiplimab in Subjects With Recurrent or Progressive Glioblastoma
Alaunos Therapeutics
Phase 2 Terminated
NCT04469699 2025-03-11
NOA11
University Hospital Muenster
Phase 2 Terminated
NCT05737212 2025-02-21
Studying the Safety, Efficacy, and Pharmacokinetic Characteristics of BNCT in Patients With Recurrent High-grade Gliomas
Dawonmedax Co., Ltd.
Phase 1/2 Terminated
NCT02722512 2025-02-18
Trial of Heat Shock Protein Peptide Complex-96 (HSPPC-96) Vaccine
Ann & Robert H Lurie Children's Hospital of Chicago
Phase 1 Terminated
NCT05324501 2025-02-10
MAGIC-G1
Biodexa Pharmaceuticals
Phase 1 Terminated
NCT01814813 2025-01-24
Vaccine Therapy With Bevacizumab Versus Bevacizumab Alone in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery
Alliance for Clinical Trials in Oncology
Phase 2 Terminated
NCT03717142 2025-01-15
Feasibility of the LUM Imaging System for Detection of Cancer to the Brain
Lumicell, Inc.
Phase NA Terminated
NCT04397679 2025-01-15
Partial Brain RT, Temozolomide, Chloroquine, and TTF Therapy for the Treatment of Newly Diagnosed Glioblastoma
Barbara Ann Karmanos Cancer Institute
Phase 1 Terminated
NCT02525692 2024-12-24
Oral ONC201 in Adult Recurrent Glioblastoma
Jazz Pharmaceuticals
Phase 2 Terminated
NCT04404569 2024-12-20
ETERNITI
Bexion Pharmaceuticals, Inc.
Phase 1 Terminated
NCT04421378 2024-12-16
A Study of Selinexor in Combination With Standard of Care Therapy for Newly Diagnosed or Recurrent Glioblastoma
Karyopharm Therapeutics Inc
Phase 1/2 Terminated
NCT05831995 2024-12-06
Safety and Effectiveness of ABM-168 in Adults with Advanced Solid Tumors.
ABM Therapeutics Corporation
Phase 1 Terminated
NCT04128774 2024-11-26
GBMdexaB
Amsterdam UMC, location VUmc
Terminated